## **ICMJE DISCLOSURE FORM**

Date: <u>Jan.27th, 202</u> Your Name: Inas	22 Abuali
•	Management of BRAF Non-V600E Mutated Metastatic NSCLC
Manuscript number (if	known): _PCM-21-49-CL
	parency, we ask you to disclose all relationships/activities/interests listed below that are
	of your manuscript. "Related" means any relation with for-profit or not-for-profit third many be affected by the content of the manuscript. Disclosure represents a commitment
•	pes not necessarily indicate a bias. If you are in doubt about whether to list a

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
_	educational events	V N		
6	Payment for expert	XNone		
	testimony			
7	Support for attending	X None		
′	meetings and/or travel			
	meetings and/or traver			
0	Determination and included an	V. Nana		
8	Patents planned, issued or pending	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
4.0	Advisory Board	V N		
10	Leadership or fiduciary role	XNone		
	in other board, society, committee or advocacy			
	group, paid or unpaid			
11		X None		
11	Stock or stock options	XNone		
12	Receipt of equipment,	V None		
12	materials, drugs, medical	X_None		
	writing, gifts or other			
	services			
13	Other financial or non-	V None		
13	financial interests	XNone		
	ווומוונומו ווונכו פטנט			
Ple	Please summarize the above conflict of interest in the following box:			
_				
	None.			

Please place an "X" next to the following statement to indicate your agreement:

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

Date: <u>Jan. 2</u>	25 <sup>th</sup> , 2022			
Your Name:	Chung-Shien Lee			
Manuscript Tit	e: Management of BRAF Non-V600E Mutated Metastatic NSCLC			
Manuscript number (if known): PCM-21-49				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial	planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone		
	Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone		
3	Royalties or licenses	XNone		
4	Consulting fees	XNone		

	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events	V Nana		
6	Payment for expert testimony	XNone		
	testimony			
7	Support for attending	X None		
•	meetings and/or travel			
	,			
8	Patents planned, issued or	X None		
	pending			
9	Participation on a Data	X None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	XNone		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	XNone		
12	Possint of aguinment	X None		
12	Receipt of equipment, materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non- financial interests	X None		
בות	Please summarize the above conflict of interest in the following box:			
rie	ricase summanze the above commet of interest in the following box.			
	None.			

Please place an "X" next to the following statement to indicate your agreement:

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

Date: January 27th, 2022

Your Name: Nagashree Seetharamu

Manuscript Title: Management of BRAF Non-V600E Mutated Metastatic NSCLC

Manuscript number (if known): PCM-21-49-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial	planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone		
	Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone		
3	Royalties or licenses	XNone		

4	Consulting fees	Boehringer Ingram	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	_Astrazeneca	
	Safety Monitoring Board or	Amgen	
	Advisory Board	Takeda	
		Regeneron	
		Genentech	
		Pfizer	
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		

Please summarize the above conflict of interest in the following box: The author has received consulting fee from Boehringer Ingram. She has been on scientific advisory board for AstraZeneca, Amgen, Takeda, Genentech, Regeneron, and Pfizer within the last 36 months. None of these have any impact on the manuscript.

Please place an "X" next to the following statement to indicate your agreement:

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.